Archive for April 2015
The Federal Circuit Holds Sandoz Cannot Bypass the BPCIA’s “Patent Dance,” but Dancing Still May Be Optional
By: Suzie Vroman In March, the Food and Drug Administration (FDA) granted approval for the first biosimilar in U.S. pharmaceutical history under the Biologics Price Competition and Innovation Act (BPCIA).[1] Biosimilars, the generic form of biologics, are not currently on the market in the United States, but this may soon change with the approval of…
Read More